Showing results (571-580 of 692) with videos related to
Sort By:
Pageof 70
Seminars in Oncology|December 1, 1990
NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's diseaseF B Hagemeister, F Cabanillas, W S Velásquez, et al.The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 14, 2004
Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor toleranceMei Xu, Michael Petraschka, Jay P McLaughlin, et al.International Journal of Radiation Oncology, Biology, Physics|September 20, 2005
A historical prospective cohort study of carotid artery stenosis after radiotherapy for head and neck malignanciesPaul D Brown, Robert L Foote, Mark P McLaughlin, et al.Blood|March 1, 1991
Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-bleo and radiotherapyW S Velasquez, L M Fuller, S Jagannath, et al.Organic & Biomolecular Chemistry|September 7, 2017
A one-pot multicomponent approach to a new series of morphine derivatives and their biological evaluationJiaan Shao, Richard A Houghten, Colette T Dooley, et al.International Journal of Radiation Oncology, Biology, Physics|January 11, 1992
Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin's diseaseS Y Woo, L M Fuller, J H Cundiff, et al.Leukemia & Lymphoma|May 30, 2001
Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcomeA M Tsimberidou, A H Sarris, L J Medeiros, et al.Chemmedchem|July 16, 2011
Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208Jane V Aldrich, Santosh S Kulkarni, Sanjeewa N Senadheera, et al.Breast (Edinburgh, Scotland)|November 6, 2022
Comparison of the Nottingham Prognostic Index and OncotypeDX© recurrence score in predicting outcome in estrogen receptor positive breast cancerEoin P Kerin, Matthew G Davey, Ray P McLaughlin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphomaA H Sarris, A Younes, P McLaughlin, et al.Pageof 70